Galectin Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$27.8MTTM through 30 Jun 2026
Free Cash Flow -$15.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
20.1%ROE
-187.8%ROA
Balance Sheet Health
Debt / Equity-1.03x
Current Ratio2.15x
Net Debt$121.6M
Cash & Equivalents$13.3M
Quality Metrics
Altman Z-Score-55.10
Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
Diluted EPS-$0.43TTMFY2025: $-0.48
Dividend
No dividend
Capital Allocation
R&D Spend$8.9M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Belapectin Program | $0 | 0.0% | View detailsThe company is actively engaging with the FDA (Type-C meeting planned) and exploring strategic partnerships to determine the optimal path forward for Phase 3 development. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.